Hasil Pencarian  ::  Simpan CSV :: Kembali

"On May 2003, the Government start the divestment of Bank Danamon's share. First, the divestment process through a strategic sale mechanism of 51% share divestment of Bank Danamon Indonesia (BDI) and second, the divestment process through market placement of 20% shares of BDI. On June 2003, the Asia Financial Indonesia Pte.Ltd Consortium (AFI Consortium) acquired 51% of IBRA shareholdings in Bank Danamon Indonesia. First divestment of 51% Bank Danamon's share invite a lot of the debates particularly concerning price offer of Bank share of Danamon by strategic investor which assessed was lower than market share.

To know do offer price given by the strategic investor lower or high, hence in this thesis will be conducted by assessment of Bank Danamon;s share. This assessment is conducted by using fundamental analysis which have the character of topdown analysis, started with macro economic analysis, last industry and company analysis. Fair value of Bank Danamon `s share calculated by using Two Stage Dividend Discount Model and Ratio Earning Price These datas to do assessment taking from secondary data through publicized financial statement, data of IHSG, rate of SBI level and other relevant publication. Assessment the intrinsic value of Bank Danamon's share use Two Stage Dividend of Discount Model was higher than offer price by Asian Financial Indonesia ( AFL) as a winner of tender so that Bank Danamon's share was undervalued or assessed too low. While result using PER still is higher than PER actual of Bank Danamon Indonesia, this matter also indicate that Bank Danamon's share was undervalued.

Because of the intrinsic value of share residing above market value hence Bank Danamon's share was good investment choice for investor candidate and investor during his value still undervalued to be bought by because it price will close to and over the intrinsic value of it. While for government, divestment of rest share for the next bank like Bank Mandiri, Bank Lippo, Bank Bali and the other bank is better not to sell until the share value of those bank more increase to get the better feedback return."

"Latar belakang: Penyakit kanker pada anak masih memiliki angka kematian yang tinggi. Pandemi Coronavirus disease 2019 (COVID-19) dapat memperlebar kesenjangan luaran pasien kanker anak di negara berkembang dengan negara maju. Data mengenai pasien kanker anak dengan COVID-19 terkonfirmasi di negara berkembang masih terbatas.Tujuan: Mengetahui prevalens dan luaran pasien kanker anak dengan COVID-19 terkonfirmasi serta faktor yang memengaruhinya agar luaran kanker dapat optimal.Metode: Penelitian ini merupakan studi prognostik dengan desain penelitian kohort retrospektif di rumah sakit rujukan nasional menggunakan data rekam medis. Subyek penelitian adalah pasien kanker anak usia 0-18 tahun dengan COVID-19 terkonfirmasi yang dirawat di pusat COVID-19 - RSCM pada Maret 2020 – Juni 2023. Data deskriptif mengenai prevalens, karakteristik, dan luaran dikumpulkan, dilakukan juga analisis untuk mengetahui pengaruh antara jenis kanker, fase pengobatan, penundaan pengobatan, dan derajat keparahan COVID-19 terhadap luaran.Hasil: Dari 585 pasien kanker anak yang dirawat, 110 (18,8%) di antaranya terkonfirmasi COVID-19 berdasarkan swab PCR SARS-COV-2. Pasien mayoritas berusia 0-5 tahun (39,1%), menderita kanker darah (50,9%), dalam fase pengobatan (88,1%), dan pengobatan tersebut tertunda sebanyak 56,4%. Gejala tersering adalah demam (78,2%), nilai CT PCR terbanyak terdeteksi di bawah 30 (54,6%), dan mayoritas mengalami COVID-19 derajat ringan (55,5%). Tata laksana yang diberikan adalah terapi oksigen (29,1%) dengan penggunaan ventilator sebanyak 8,2% dan dirawat di PICU sebanyak 12,7%, pemberian antivirus (69,1%), antibiotik (80,9%), antiinflamasi (14,5%), dan antikoagulan (22,7%). Sebanyak 19,1% kasus meninggal dan mayoritas terjadi pada 14 hari pertama perawatan. Kesintasan kumulatif adalah 66,1% dan rerata kesintasan selama 40 hari (IK 95% 33,743-46,064). Jenis kanker, fase pengobatan, dan penundaan pengobatan tidak berpengaruh bermakna terhadap luaran kematian. Sementara, derajat keparahan COVID-19 berpengaruh bermakna terhadap luaran kematian dengan HR 4,38 (IK 95% 1,34-14,26; p=0,000) pada derajat sedang/berat dan HR 16,29 (IK 95% 4,83-54,8; p=0,014) pada derajat kritis.Simpulan: Prevalens dan angka kematian pasien kanker anak dengan COVID-19 terkonfirmasi lebih tinggi dibanding COVID-19 pada anak secara keseluruhan, terutama di negara berkembang. Penundaan kemoterapi dapat dipertimbangkan, terutama dalam 14 hari pertama perawatan di rumah sakit.

---

Background: Pediatric cancer still has a high mortality rate. The Coronavirus disease 2019 (COVID-19) pandemic has further widened the disparity in pediatric cancer outcomes between developing and developed countries. Limited data exist on the prevalence and consequences of pediatric cancer with confirmed COVID-19 in developing countries.

Objectives: To determine the prevalence and outcomes of these patients and identify influencing factors to optimize cancer outcomes.

Method: This prognostic study employed a retrospective cohort design at a tertiary referral hospital in Indonesia using medical record data. Subjects included pediatric cancer patients aged 0-18 years with confirmed COVID-19 treated at the Kiara COVID-19 Center – dr. Cipto Mangunkusumo Hospital from March 2020 to June 2023. Descriptive data on prevalence, characteristics, and outcomes were collected, along with analysis of the relationship between cancer type, treatment phase, delayed treatment, and COVID-19 severity.

Result: Among 585 pediatric cancer patients treated, 110 (18.8%) were confirmed COVID-19 based on SARS-COV-2 PCR. The majority were aged 0-5 years (39,1%), diagnosed with blood cancer (50,9%), undergoing radio-chemotherapy (88,1%), and delayed treatment 56,4%. Fever was the most prevalent symptom (78.2%), the most CT PCR values were below 30 (54,6%), with 55,5% experiencing mild COVID-19. Management included oxygen therapy (29,1%) with ventilator use (8.2%) and intensive care (12.7%), antiviral (69.1%), antibiotic (80.9%), anti-inflammatory (14.5%), and anticoagulant (22.7%). The mortality rate was 19,1% and the highest number of deaths occurred within 14 days of hospitalization. Cumulative survival was 66.1% and a mean survival was 40 days (95% CI 33.743-46.064). Cancer type, treatment phase, and delayed treatment were not association with mortality outcomes. Meanwhile, COVID-19 severity was associated with mortality outcomes with HR 4.38 (95% CI 1.34-14.26; p=0.000) in moderate/severe COVID-19 and 16.29 (95% CI 4.83-54.8; p=0.014) in critical case.

Conclusion: The prevalence and mortality rates of pediatric cancer with confirmed COVID-19 are notably higher than the general pediatric COVID-19, especially in developing countries. Chemotherapy may be considered postponed, particularly within the first 14 days of hospitalization."